Literature DB >> 28509214

Severe metabolic alkalosis, hypokalemia, and respiratory acidosis induced by the Chinese herbal medicine yokukansan in an elderly patient with muscle weakness and drowsiness.

Shunsuke Yamada1,2, Masanori Tokumoto3, Yasuo Kansui3, Yoshinobu Wakisaka3, Yuji Uchizono3, Kazuhiko Tsuruya4, Hiroaki Ooboshi3.   

Abstract

Yokukansan is a Chinese herbal medicine containing licorice that has been shown to alleviate the behavioral and psychological symptoms of Alzheimer's disease, with few adverse effects. Increasing numbers of patients with Alzheimer's disease in Japan are now being treated with this drug. However, yokukansan should be used with caution because of its potential to induce pseudoaldosteronism through the inhibition of 11-beta-hydroxysteroid dehydrogenase type 2, which metabolizes cortisol into cortisone. We present the case of an 88-year-old woman with a history of Alzheimer's disease who was transferred to our emergency department because of drowsiness, anorexia, and muscle weakness. Her blood pressure was 168/90 mmHg. Laboratory data showed serum potassium of 1.9 mmol/l, metabolic alkalosis (pH 7.54; HCO 3- , 50.5 mmol/l; chloride, 81 mmol/l; sodium, 140 mmol/l), and respiratory disorders (pCO2, 60.5 mmHg; pO2, 63.8 mmHg). Plasma renin activity and aldosterone concentration were suppressed, and urinary potassium excretion was 22 mmol/l (calculated transtubular potassium gradient 12.9). An electrocardiogram showed flat T-waves and U-waves with ventricular premature contractions. Echocardiography denied volume depletion. Medical interview disclosed that she had been treated with a Chinese herbal medicine (yokukansan) containing licorice. The final diagnosis was pseudoaldosteronism and respiratory acidosis induced by licorice. Hypokalemia, metabolic alkalosis, and respiratory acidosis all subsided shortly after the discontinuation of yokukansan and initiation of intravenous potassium replacement. This case highlights the need for nephrologists to consider the possible involvement of Chinese herbal medicines, including yokukansan, when they encounter hypokalemia in elderly patients.

Entities:  

Keywords:  Herbal medicine; Hypokalemia; Licorice; Metabolic alkalosis; Yokukansan

Year:  2012        PMID: 28509214      PMCID: PMC5413722          DOI: 10.1007/s13730-012-0032-3

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  18 in total

1.  A case of severe hypokalemic paralysis and hypertension. Licorice-induced hypokalemic paralysis.

Authors:  Prajwol Pant; Lakshmi Nadimpalli; Mukesh Singh; Jen Chieh Cheng
Journal:  Am J Kidney Dis       Date:  2010-06       Impact factor: 8.860

2.  In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice.

Authors:  P Ferrari; A Sansonnens; B Dick; F J Frey
Journal:  Hypertension       Date:  2001-12-01       Impact factor: 10.190

3.  Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice.

Authors:  Yoshihito Hayashi; Yasushi Ishida; Teruhiko Inoue; Mitsutaka Udagawa; Kouzou Takeuchi; Hirofumi Yoshimuta; Kouichirou Kiue; Yoshimasa Ninomiya; Jiro Kawano; Tetsuro Sameshima; Takashi Kawahara; Isamu Goto; Kenji Shudo; Shigeki Kurayama; Jungo Nakamura; Kazunori Okahara; Yoshio Mitsuyama
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-02-23       Impact factor: 5.067

4.  Open label trial to evaluate the efficacy and safety of Yokukansan, a traditional Asian medicine, in dementia with Lewy bodies.

Authors:  Koh Iwasaki; Kenji Kosaka; Hideo Mori; Reina Okitsu; Katsutoshi Furukawa; Yuta Manabe; Mitsuhiro Yoshita; Aya Kanamori; Nobuo Ito; Kenji Wada; Michio Kitayama; Jun Horiguchi; Shuhei Yamaguchi; Ryuji Fukuhara; Shinji Ouma; Seigo Nakano; Mamoru Hashimoto; Toru Kinoshita
Journal:  J Am Geriatr Soc       Date:  2011-05       Impact factor: 5.562

5.  Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.

Authors:  J L Arriza; C Weinberger; G Cerelli; T M Glaser; B L Handelin; D E Housman; R M Evans
Journal:  Science       Date:  1987-07-17       Impact factor: 47.728

6.  [Effects of long term administration of Shakuyaku-kanzo-To and Shosaiko-To on serum potassium levels].

Authors:  Masato Homma; Miya Ishihara; Wen Qian; Yukinao Kohda
Journal:  Yakugaku Zasshi       Date:  2006-10       Impact factor: 0.302

Review 7.  Disorders of potassium homeostasis: an approach based on pathophysiology.

Authors:  K S Kamel; S Quaggin; A Scheich; M L Halperin
Journal:  Am J Kidney Dis       Date:  1994-10       Impact factor: 8.860

8.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

9.  A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia.

Authors:  Katsuyoshi Mizukami; Takashi Asada; Toru Kinoshita; Katsuaki Tanaka; Kazuki Sonohara; Ryuhei Nakai; Kiyoshi Yamaguchi; Haruo Hanyu; Kiyoshi Kanaya; Tetsuya Takao; Masakatsu Okada; Sumio Kudo; Hayato Kotoku; Masahiko Iwakiri; Hirofumi Kurita; Toshihiro Miyamura; Yosuke Kawasaki; Koji Omori; Kazumasa Shiozaki; Toshinari Odawara; Tatsuya Suzuki; Shizuru Yamada; Youichi Nakamura; Kenji Toba
Journal:  Int J Neuropsychopharmacol       Date:  2008-12-11       Impact factor: 5.176

10.  Severe hypokalemia, rhabdomyolysis, muscle paralysis, and respiratory impairment in a hypertensive patient taking herbal medicines containing licorice.

Authors:  Hirofumi Yasue; Teruhiko Itoh; Yuji Mizuno; Eisaku Harada
Journal:  Intern Med       Date:  2007-05-01       Impact factor: 1.271

View more
  1 in total

1.  Liquorice-induced hypokalaemia in patients treated with Yokukansan preparations: identification of the risk factors in a retrospective cohort study.

Authors:  Saori Shimada; Tetsuaki Arai; Akira Tamaoka; Masato Homma
Journal:  BMJ Open       Date:  2017-06-15       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.